Clinuvel Pharmaceuticals (ASX:CUV) Scaled Net Operating Assets : 0.03 (As of Dec. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Clinuvel Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Clinuvel Pharmaceuticals's operating assets for the quarter that ended in Dec. 2023 was A$37.23 Mil. Clinuvel Pharmaceuticals's operating liabilities for the quarter that ended in Dec. 2023 was A$31.96 Mil. Clinuvel Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was A$193.71 Mil. Therefore, Clinuvel Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.03.

Clinuvel Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Scaled Net Operating Assets Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.08

0.13

0.21

0.05

0.06

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.09	0.05	-	0.06	0.03

Competitive Comparison of Clinuvel Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Scaled Net Operating Assets falls into.

Clinuvel Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Clinuvel Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2023 )
=	(Operating Assets (A: Jun. 2023 )	-	Operating Liabilities (A: Jun. 2023 ))	/	Total Assets (A: Jun. 2022 )
=	(36.9	-	28.082)	/	143.95
=	0.06

where

	Operating Assets		(A: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	193.714	-	156.814
=	36.9

	Operating Liabilities		(A: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	29.082	-	0.699	-	0.301
=	28.082

Clinuvel Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(37.232	-	31.962)	/	193.714
=	0.03

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	211.681	-	174.449
=	37.232

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	33.031	-	0.713	-	0.356
=	31.962

Clinuvel Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (ASX:CUV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (ASX:CUV) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

CLVLY:USA CLVLF:USA UR9:Germany

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (ASX:CUV) Headlines

No Headlines